| scholarly article | Q13442814 |
| P2093 | author name string | George K Lewis | |
| Anthony L DeVico | |||
| Mohammad M Sajadi | |||
| Amir Dashti | |||
| P2860 | cites work | Potent and broad HIV-neutralizing antibodies in memory B cells and plasma | Q40092127 |
| Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design | Q40296420 | ||
| Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. | Q40346802 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. | Q40449526 | ||
| Determinants of HIV-1 broadly neutralizing antibody induction. | Q40476608 | ||
| Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design | Q40679052 | ||
| CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. | Q41151327 | ||
| HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex | Q41379235 | ||
| A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. | Q41419602 | ||
| Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators. | Q43610425 | ||
| Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients | Q44255828 | ||
| Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity | Q46168513 | ||
| A single, continuous metric to define tiered serum neutralization potency against HIV. | Q47551447 | ||
| Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against clade B clinical isolates produced in peripheral blood mononuclear cells | Q47566038 | ||
| Development of the antibody response in acute HIV-1 infection | Q47747470 | ||
| Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope | Q52338929 | ||
| Superinfection Drives HIV Neutralizing Antibody Responses from Several B Cell Lineages that Contribute to a Polyclonal Repertoire | Q52718554 | ||
| Immune systems rather than antigenic epitopes elicit and produce protective antibodies against HIV. | Q54686508 | ||
| Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. | Q55347049 | ||
| HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes | Q56913214 | ||
| Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? | Q56974226 | ||
| Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level | Q58038022 | ||
| Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials | Q58038926 | ||
| Engineering multi-specific antibodies against HIV-1 | Q58696428 | ||
| Tracing HIV-1 strains that imprint broadly neutralizing antibody responses | Q59054303 | ||
| Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition | Q59350200 | ||
| Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies | Q59353026 | ||
| Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses | Q88582157 | ||
| Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals | Q24635002 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| HIV broadly neutralizing antibody targets | Q27026662 | ||
| Antibody domain exchange is an immunological solution to carbohydrate cluster recognition | Q27641517 | ||
| Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody | Q27644415 | ||
| Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
| Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies | Q27644515 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing | Q27671696 | ||
| Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies | Q27674878 | ||
| Broad and potent neutralization of HIV-1 by a gp41-specific human antibody | Q27675131 | ||
| Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody | Q27677011 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization | Q27677117 | ||
| Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 | Q27678306 | ||
| Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies | Q27679353 | ||
| Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor | Q27684529 | ||
| Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies | Q28602877 | ||
| CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization | Q28646881 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Survivors Remorse: antibody-mediated protection against HIV-1. | Q30238730 | ||
| Evolutionary and immunological implications of contemporary HIV-1 variation. | Q30329205 | ||
| Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. | Q30369026 | ||
| Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. | Q30490942 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| Measuring HIV neutralization in a luciferase reporter gene assay | Q39914262 | ||
| Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection | Q33410222 | ||
| Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance | Q33591736 | ||
| Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies | Q33614365 | ||
| Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables | Q33614495 | ||
| Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. | Q33636347 | ||
| Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. | Q33693391 | ||
| Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection | Q33702217 | ||
| HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies | Q33753573 | ||
| Early development of broadly neutralizing antibodies in HIV-1-infected infants | Q33764917 | ||
| Characteristics of the earliest cross-neutralizing antibody response to HIV-1. | Q33798076 | ||
| Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes | Q33805324 | ||
| Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects | Q33888559 | ||
| Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. | Q34009945 | ||
| Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses | Q34023249 | ||
| A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals | Q34047445 | ||
| Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies | Q34114798 | ||
| Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques | Q34230556 | ||
| Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles | Q34406977 | ||
| Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface | Q34473958 | ||
| HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption | Q34531858 | ||
| Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo | Q34593860 | ||
| Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex | Q34709433 | ||
| Evidence for a Continuous Drift of the HIV-1 Species towards Higher Resistance to Neutralizing Antibodies over the Course of the Epidemic | Q34819651 | ||
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia | Q34848486 | ||
| Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 | ||
| Polyreactivity and autoreactivity among HIV-1 antibodies | Q34992787 | ||
| Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. | Q35034034 | ||
| Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 | Q35192782 | ||
| Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated | Q35441583 | ||
| Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection | Q35641234 | ||
| Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent | Q35686912 | ||
| Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies | Q35743897 | ||
| Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors | Q35857221 | ||
| Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design | Q35868076 | ||
| Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort | Q35894094 | ||
| Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection | Q35914292 | ||
| Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma. | Q35943730 | ||
| Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization | Q36081789 | ||
| Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 | Q36132925 | ||
| The development of CD4 binding site antibodies during HIV-1 infection | Q36155396 | ||
| HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. | Q36345558 | ||
| λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies | Q36365309 | ||
| Antigenic conservation and immunogenicity of the HIV coreceptor binding site | Q36403587 | ||
| Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo | Q36414891 | ||
| Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10. | Q36485204 | ||
| Antibody polyspecificity and neutralization of HIV-1: a hypothesis | Q36487151 | ||
| Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. | Q36623941 | ||
| Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. | Q36961578 | ||
| Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies | Q37033269 | ||
| Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals | Q37033400 | ||
| Visualizing antibody affinity maturation in germinal centers | Q37078589 | ||
| Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination | Q37119451 | ||
| Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 | ||
| Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors | Q37333772 | ||
| Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression | Q37356036 | ||
| High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination | Q37471315 | ||
| Antigenic properties of the HIV envelope on virions in solution | Q37547245 | ||
| Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. | Q37547462 | ||
| Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption | Q37624842 | ||
| Native-like Env trimers as a platform for HIV-1 vaccine design | Q37633417 | ||
| Accessing the human repertoire for broadly neutralizing HIV antibodies | Q37694976 | ||
| Polyreactive antibodies in adaptive immune responses to viruses | Q37951868 | ||
| Basic research in HIV vaccinology is hampered by reductionist thinking | Q38025633 | ||
| Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody | Q38476940 | ||
| Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers | Q39001126 | ||
| Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection | Q39278529 | ||
| CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. | Q39605077 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 228-240 | |
| P577 | publication date | 2019-02-18 | |
| P1433 | published in | Trends in Molecular Medicine | Q15265842 |
| P1476 | title | Broadly Neutralizing Antibodies against HIV: Back to Blood | |
| P478 | volume | 25 |
| Q91636324 | Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV |
| Q89803127 | Shortening HIV vaccine regimens to achieve high coverage |
| Q91609981 | Strategies for inducing effective neutralizing antibody responses against HIV-1 |
| Q92538999 | Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization |
Search more.